• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.

作者信息

Luo Hui, Li Tongjuan, Meng Fankai, Hong Zhenya, Cao Yang, Wang Gaoxiang, Huang Liang, Zhou Xiaoxi

机构信息

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan 430030, China.

出版信息

Cancer Biol Med. 2025 May 6;22(5):496-501. doi: 10.20892/j.issn.2095-3941.2024.0626.

DOI:10.20892/j.issn.2095-3941.2024.0626
PMID:40329502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12240193/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41e1/12240193/352dd95d52f8/cbm-22-05-496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41e1/12240193/352dd95d52f8/cbm-22-05-496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41e1/12240193/352dd95d52f8/cbm-22-05-496-g001.jpg

相似文献

1
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.嵌合抗原受体（CAR）T细胞疗法治疗复发/难治性CD5阳性弥漫性大B细胞淋巴瘤的效果优于标准疗法。
Cancer Biol Med. 2025 May 6;22(5):496-501. doi: 10.20892/j.issn.2095-3941.2024.0626.
2
The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.放疗在CAR-T治疗后复发或难治性弥漫性大B细胞淋巴瘤中的作用：一项系统文献综述
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251351065. doi: 10.1177/15330338251351065. Epub 2025 Jun 18.
3
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
4
Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report.联合自体造血干细胞移植和CD19嵌合抗原受体T细胞疗法治疗伴有 突变的复发/难治性弥漫性大B细胞淋巴瘤：1例报告
SAGE Open Med Case Rep. 2025 Mar 11;13:2050313X241306236. doi: 10.1177/2050313X241306236. eCollection 2025.
5
Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.病例报告：难治性ALK阳性间变性大细胞淋巴瘤患者中高度扩增的抗CD5嵌合抗原受体T细胞与复发淋巴瘤细胞的鉴别诊断
Front Immunol. 2023 Dec 8;14:1280007. doi: 10.3389/fimmu.2023.1280007. eCollection 2023.
6
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
7
Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.美国复发或难治性弥漫性大B细胞淋巴瘤患者治疗相关神经毒性的经济负担
Am Health Drug Benefits. 2020 Oct-Nov;13(5):192-199.
8
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy.改善复发难治性弥漫性大B细胞淋巴瘤的治疗效果：CAR T细胞疗法的作用
Curr Treat Options Oncol. 2025 Apr 28. doi: 10.1007/s11864-025-01305-9.
9
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.异基因CD5特异性嵌合抗原受体T细胞疗法治疗复发/难治性T细胞急性淋巴细胞白血病：一项1期试验。
Nat Med. 2025 Jan;31(1):126-136. doi: 10.1038/s41591-024-03282-2. Epub 2024 Oct 1.
10
Enrichment of CD7CXCR3 CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma.输注产品中CD7CXCR3嵌合抗原受体T细胞的富集与复发或难治性弥漫性大B细胞淋巴瘤的持久缓解相关。
Ann Oncol. 2025 Jul;36(7):749-761. doi: 10.1016/j.annonc.2025.03.011. Epub 2025 Mar 23.

本文引用的文献

1
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.一线使用阿基仑赛治疗高危大B细胞淋巴瘤的三年随访分析：ZUMA-12研究
Blood. 2025 May 15;145(20):2303-2311. doi: 10.1182/blood.2024027347.
2
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
3
Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.
初发性 CD5+弥漫性大 B 细胞淋巴瘤的临床病理特征和基因组特征：一项多中心合作研究。
Am J Surg Pathol. 2022 Nov 1;46(11):1533-1544. doi: 10.1097/PAS.0000000000001957. Epub 2022 Aug 26.
4
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.单独或联合 ASCT 使用 CAR T 细胞鸡尾酒治疗伴有 TP53 改变的侵袭性 B 细胞淋巴瘤的结果。
Signal Transduct Target Ther. 2022 Apr 11;7(1):101. doi: 10.1038/s41392-022-00924-0.
5
Influence of Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.CAR-T细胞时代突变对弥漫性大B细胞淋巴瘤生存的影响
Cancers (Basel). 2021 Nov 9;13(22):5592. doi: 10.3390/cancers13225592.
6
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
7
CD5+ diffuse large B-cell lymphoma: a narrative review.CD5阳性弥漫性大B细胞淋巴瘤：一篇叙述性综述
Leuk Lymphoma. 2021 Dec;62(13):3078-3086. doi: 10.1080/10428194.2021.1953010. Epub 2021 Jul 21.
8
Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR.通过液滴数字 PCR 与实时 PCR 检测和定量嵌合抗原受体转基因拷贝数。
J Mol Diagn. 2020 May;22(5):699-707. doi: 10.1016/j.jmoldx.2020.02.007.
9
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
10
Toxicities of chimeric antigen receptor T cells: recognition and management.嵌合抗原受体T细胞的毒性：识别与管理
Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.